Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCavis(TM) #cancer #heartdisease #inflammation #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals
First pipeline asset from Yellowbird's platform to enter clinical development Phase I trial evaluating NeuCaVis™ in healthy volunteers Phase I completion anticipated June 2026 Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation.To view an enhanced version of...
http://dlvr.it/TS3CQW
http://dlvr.it/TS3CQW
Comments
Post a Comment